StockNYSE · US · USDHealthcare · Medical Care Facilities
$AUNA
AUNA S.A.
Auna operates hospitals, clinics and outpatient facilities in Mexico, Peru and Colombia, and provides prepaid healthcare plans in Peru and Mexico. Its services focus on prevention and medium- to high-complexity care, including oncology, cardiology, neurology, trauma and orthopedics. The company’s four segments are Healthcare Services in Mexico, Healthcare Services in Peru, Healthcare Services in Colombia and Oncosalud Peru, which includes prepaid healthcare plans and oncology services. Auna earns money from healthcare services delivered through its facilities, prepaid healthcare plans, and insurance products. In Mexico, Auna Seguros offers dental and vision plans and sells oncology plans; in Peru, Oncosalud offers oncology-focused plans alongside general healthcare plans. As of December 31, 2025, Auna’s network includes 15 hospitals with 2,333 beds and 16 outpatient, prevention and wellness facilities. Auna is headquartered in Luxembourg.
Auna S.A. reported Q3 2026 revenue of S/1,325 million, up 10% FXN, with free cash flow doubling YoY. Adjusted EBITDA was flat YoY at S/231 million, with margins compressing. Stock traded at $4.84 premarket, up 1.47%. Challenges included currency depreciation and regulatory headwinds in key markets.
AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro
Auna S.A. revised its 2026 outlook, expecting flat Adjusted EBITDA due to temporary cost pressures from a Colombia payor contract, while revenue growth remains in line with prior guidance.
via TradingView
AUNA sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning AUNA (AUNA S.A.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 3 bearish.
Recent AUNA coverage spans earnings and financial news.
What's driving AUNA
Strong top-line and cash flow contrasted with margin pressure and revised profitability guidance, likely driving a mixed near-term tape reaction.
Guidance update and profitability headwinds in Colombia and Peru are likely to drive near-term sentiment, despite strong cash generation and leverage improvement.
Auna S.A. revised its 2026 outlook, expecting flat Adjusted EBITDA due to temporary cost pressures from a Colombia payor contract, while revenue growth remains in line with prior guidance.
AlphAI scores every news story that mentions AUNA with an AI model for sentiment and relevance, and aggregates insider trades from AUNA S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Auna S.A. reported Q3 2026 revenue of S/1,325 million, up 10% FXN, with free cash flow doubling YoY. Adjusted EBITDA was flat YoY at S/231 million, with margins compressing. Stock traded at $4.84 premarket, up 1.47%. Challenges included currency depreciation and regulatory headwinds in key markets.
AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro
Auna S.A. revised its 2026 outlook, expecting flat Adjusted EBITDA due to temporary cost pressures from a Colombia payor contract, while revenue growth remains in line with prior guidance.
Auna S.A. (AUNA) has met all conditions to start building the Centro Ambulatorio Trecca under a PPP with EsSalud. Construction begins now, with operations expected to start in late 2028. The project has guaranteed minimum volumes.
Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.
Auna reported Q2 revenue growth in Mexico (4% YoY), Peru (8%), and Colombia (13%), but adjusted EBITDA varied. Mexico's EBITDA declined 16% YoY due to investments, while Peru's was flat due to billing penalties. Colombia's EBITDA fell 12% YoY but rose 18% sequentially. The company reaffirmed its full-year guidance, expecting 12% FX-neutral revenue growth and adjusted EBITDA growth toward the low end of its 10-14% target range, excluding Peru's billing penalties. Cash flow and leverage improved,
Auna S.A. reported Q2 2026 revenue growth of 9%, driven by high-complexity services, with adjusted EBITDA declining 9% due to investment costs. Management reaffirmed full-year revenue guidance of 12% growth and expects EBITDA growth at the low end of 10-14%. Free cash flow increased 181% due to working capital management. The company faces short-term penalties in Peru but anticipates improvements in profitability and cash flow.
Auna S.A. (NYSE: AUNA) reported 2Q26 results with revenue up 9% FX-neutral to S/1,238 million, but Adjusted EBITDA down 9% FX-neutral to S/227 million. Operating cash flow and free cash flow rose 45% and 181% YoY, respectively. The company attributed EBITDA declines to service mix and cost pressures across its Latin American markets. Auna reaffirmed its full-year revenue guidance of 12% growth and expects Adjusted EBITDA growth at the low end of its 10-14% range.
AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 2Q26 Financial Results A consecutive quarter of strong top-line growth and cash flow performance; Consolidated Adjusted EBITDA impacted by service mix across the segments Luxembourg, August 18, 2026 – Auna (NYSE: AUNA) (“Auna” or the “Company”) , a lea
Auna S.A. (NYSE:AUNA) is covered by seven analysts. The average target implies ~32.6% upside, but JPMorgan on May 26 kept a Hold rating and cut its price target to $5 from $6. S&P Global shows a Buy consensus with an average target of $6.99. Fitch affirmed a B+ rating on May 22, citing material leverage; the outlook depends on execution across Latin American healthcare services.